1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Developing an optimal fully-human CD371-targeting IL-18 secreting CART cell for the treatment of acute myeloid leukemia
    Meeting Abstract

    Shahid, S.; Mathew, S.; Souness, S.; Burns, E. R.; Um, J. S.; Yoo, S.; Cai, W.; Pohl, M. A.; Fujino, T.; Zhang, P.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Improvement in serum albumin as a measure of improved metabolic profile in pacritinib-treated patients: A retrospective analysis of patients treated across three clinical trials
    Meeting Abstract

    Palandri, F.; Sobas, M.; Harrison, C.; Rampal, R.; Buckley, S.; Suthar, P.; Roman-Torres, K.; Mascarenhas, J. O.
    Blood (2024)

    Fulltext@MSK | Save
  • Cytokine modulation correlates strongly with symptom improvement in patients with myelofibrosis treated with nuvisertib (TP-3654), an investigational selective PIM1 kinase inhibitor
    Meeting Abstract

    Rein, L. A. M.; El Chaer, F.; Yuda, J.; Shimoda, K.; Rampal, R.; Scandura, J. M.; Takami, A.; McCloskey, J.; Ichii, M.; Shirane, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Updated results from the phase 3 MANIFEST-2 study of pelabresib in combination with ruxolitinib for Janus kinase inhibitor-naive patients with myelofibrosis
    Meeting Abstract

    Mascarenhas, J. O.; Grosicki, S.; Chraniuk, D.; Abruzzese, E.; Bose, P.; Gerds, A. T.; Vannucchi, A. M.; Palandri, F.; Lee, S. E.; Gupta, V.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • 5-year follow-up of the phase 2 optic study in patients with chronic-phase chronic myeloid leukemia: Efficacy, safety, and first end-of-treatment mutational results
    Meeting Abstract

    Cortes, J. E.; Deininger, M. W.; Apperley, J.; Arthur, C. K.; Chuah, C.; Hochhaus, A.; de Lavallade, H.; Lipton, J. H.; Lomaia, E.; McCloskey, J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Duvelisib in patients with relapsed/refractory peripheral T-cell lymphoma: Final results from the phase 2 PRIMO trial
    Meeting Abstract

    Mehta-Shah, N.; Zinzani, P. L.; Jacobsen, E. D.; Zain, J.; Mead, M.; Casulo, C.; Gritti, G.; Pinter-Brown, L. C.; Izutsu, K.; Bentur, O. S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Patients with AML and an IDH2-R172 mutation exhibit a unique response to intensive induction chemotherapy, suggesting futility of mid-cycle bone marrow biopsy and caution when considering re-induction
    Meeting Abstract

    Yisraeli Salman, M.; Terry, A. R.; Derkach, A.; Nemirovsky, D.; Chin, K. K.; Valtis, Y. K.; Boussi, L.; Spivey, T.; Xiao, W.; Famulare, C.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Pembrolizumab for front-line treatment of extranodal NK/T-cell lymphoma
    Meeting Abstract

    Moskowitz, A.; Advani, R. H.; Ganesan, N.; Chang, T.; Hancock, H.; Davey, T.; Miller, T.; Gibaldi, A.; Smith, M.; Assini, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Final response and survival results from a phase II trial of pembrolizumab and entinostat in relapsed/refractory Hodgkin lymphoma
    Meeting Abstract

    Stuver, R.; Vardhana, S. A.; Ganesan, N.; Boardman, A. P.; Caron, P.; Chang, T.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Codon-specific differences in RAS mutations in AML and differential response to therapeutic agents
    Meeting Abstract

    Anandappa, A. J.; Trivedi, V.; Merlinsky, T.; Delgaudio, N.; Guzzardi, E.; Wooten, A.; Starczynowski, D.; Bowman, R. L.; Levine, R.; Miles, L. A.
    Blood (2024)

    Fulltext@MSK | Save